ARCHIVES

Phase II Imbruvica Trial Shows 47% of MCL Patients Alive at 27-Month Median Follow-up

This article is from The Cancer Letter archive.

Vol. 37 No. 12 | December 26, 2014

Download PDF Visit The Full Archive

Related Articles

AIDS Biological Specimens Available From NIH

November 22, 1985

New Staff Proposals For Comprehensive Center Recognition Considered By NCAB

January 19, 1979

MIT’s Sharp To Head Biology Dept.; Hynes To Head Cancer Center

April 12, 1991

Timothy Talbot, Fox Chase Founder, Centers Advocate, Dies At Age 72

November 11, 1988

BRMP Projects Priority Rated

April 11, 1980

Five NIH study section members resign over peer review of their grant proposals. Review inequitable for study section members, they say.

June 24, 2005